Navigation Links
Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
Date:6/27/2008

KENILWORTH and WHITEHOUSE STATION, N.J., June 27 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) announce the withdrawal of the New Drug Application (NDA) for the loratadine/montelukast combination tablet.

The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture, which was formed in May 2000 to develop and market a fixed-combination product that would combine loratadine and montelukast. This action has no impact on the business of the Merck/Schering-Plough cholesterol joint venture.

The U.S. Food and Drug Administration (FDA) issued on April 25, 2008 a not-approvable letter for the proposed fixed-dose combination of loratadine and montelukast.

As a result of the termination of the respiratory joint venture, Schering- Plough expects to receive payments totaling $105 million from Merck as specified in the joint venture agreements which Schering-Plough will recognize over the remaining three quarters of 2008.


'/>"/>
SOURCE Schering-Plough Corp.; Merck & Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
2. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
3. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
4. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
5. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
7. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
8. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
9. Schering-Plough CEO to Buy $2 Million in Common Shares
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Huntington Beach, CA (PRWEB) , ... January 19, ... ... for Oral Health, is now offering treatments for patients with sleep apnea and ... far-reaching consequences for dental and physical health. Dr. Rassouli provides personalized care to ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... protection and financial planning services to communities throughout eastern Georgia, is embarking on ... heart disease. , Heart disease kills more Americans every year than anything else, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages to prevent ... contest from Impact Teen Drivers and California Casualty. Entries from students aged 14-22 ... grants totaling $15,000 will be awarded for the best peer-to-peer messages sharing solutions ...
(Date:1/19/2017)... ... 19, 2017 , ... The 21st Century Cures Act’s Impact on Medical Devices:, ... 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , ... to thrive this year? , The passage of the act means devicemakers will be ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... American Osteopathic College of Proctology) announced today the opening of 3 medical ... ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... January 19, 2017 While ... serious about reducing the FDA,s regulatory strictness as ... the medical drug industry, many of the leading ... clinical trials and development of advanced drug treatments ... with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: